lecanemab
antibody · Eisai / Biogen · APOE as stratifier
Current state
- Status
- Approved — 3 active of 4 tracked studies
- Sponsor
- Eisai / Biogen
- Modality
- antibody
- Mechanism
- anti-amyloid, APOE4-stratified ARIA risk
- Thesis
- APOE as stratifier
- Record checked
- Verified by a curator
- Last change
- (2 days ago)
- Last reviewed
- (2 days ago)
Trials — 4
| NCT | Title | Phase | Status | Start | Primary completion | N | APOE-strat. |
|---|---|---|---|---|---|---|---|
| NCT01767311 | A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease | PHASE2 | COMPLETED | 856 | no | ||
| NCT03887455 | A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | PHASE3 | ACTIVE_NOT_RECRUITING | 1906 | no | ||
| NCT04468659 | AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid | PHASE3 | ACTIVE_NOT_RECRUITING | 1400 | no | ||
| NCT05925621 | Cognitive Neurology Unit Clinical Registry | — | RECRUITING | 500 | no |
Publications — 0
No linked publication. Nothing has been resolved to this therapeutic in Europe PMC or OpenAlex. Where nobody has checked the record yet, this usually means the identifier is used inconsistently in the literature rather than that no work exists.
Change history — 1
Cognitive Neurology Unit Clinical Registry
new study registeredNCT05925621
No changes match the current filter. 0 high, 1 medium and 0 low-significance changes are in this snapshot — re-enable a level above to see them.